Works by Kumakura, Yuji

Results: 20
    1

    Prognostic Nutrition Index as a Biomarker for Treatment Sensitivity to Chemotherapy and Nivolumab as the First-Line Treatment in Patients with Unresectable Advanced or Recurrent Gastric Cancer: A Multicenter Study.

    Published in:
    Oncology, 2025, v. 103, n. 6, p. 469, doi. 10.1159/000541544
    By:
    • Nakazawa, Nobuhiro;
    • Sano, Akihiko;
    • Kumakura, Yuji;
    • Yamashita, Toshiki;
    • Tanaka, Naritaka;
    • Saito, Kana;
    • Kimura, Akiharu;
    • Kasuga, Kengo;
    • Nakazato, Kenji;
    • Yoshinari, Daisuke;
    • Shimizu, Hisashi;
    • Ubukata, Yasunari;
    • Hosaka, Hisashi;
    • Shiraishi, Takuya;
    • Sakai, Makoto;
    • Sohda, Makoto;
    • Shirabe, Ken;
    • Saeki, Hiroshi
    Publication type:
    Article
    2
    3

    High expression of carcinoembryonic antigen and telomerase reverse transcriptase in circulating tumor cells is associated with poor clinical response to the immune checkpoint inhibitor nivolumab.

    Published in:
    Oncology Letters, 2018, v. 15, n. 3, p. 3061, doi. 10.3892/ol.2017.7671
    By:
    • Bao, Halin;
    • Bai, Tuya;
    • Takata, Koji;
    • Yokobori, Takehiko;
    • Ohnaga, Takashi;
    • Hisada, Takeshi;
    • MaENo, Toshitaka;
    • Bao, Pinjie;
    • Yoshida, Tomonori;
    • Kumakura, Yuji;
    • Honjo, Hiroaki;
    • Sakai, Makoto;
    • Sohda, Makoto;
    • Fukuchi, Minoru;
    • Altan, Bolag;
    • Handa, Tadashi;
    • Ide, MunENori;
    • Miyazaki, Tatsuya;
    • Ogata, Kyoichi;
    • Oyama, Tetsunari
    Publication type:
    Article
    4
    5

    Identification of Biomarkers for Assessing Treatment Efficacy of Chemotherapy plus Nivolumab as the First Line in Patients with Unresectable Advanced or Recurrent Gastric Cancer: A Multicenter Study.

    Published in:
    Oncology, 2025, v. 103, n. 3, p. 201, doi. 10.1159/000540841
    By:
    • Nakazawa, Nobuhiro;
    • Sohda, Makoto;
    • Hosoi, Nobuhiro;
    • Watanabe, Takayoshi;
    • Kumakura, Yuji;
    • Yamashita, Toshiki;
    • Tanaka, Naritaka;
    • Saito, Kana;
    • Kimura, Akiharu;
    • Kasuga, Kengo;
    • Nakazato, Kenji;
    • Yoshinari, Daisuke;
    • Shimizu, Hisashi;
    • Ubukata, Yasunari;
    • Hosaka, Hisashi;
    • Sano, Akihiko;
    • Sakai, Makoto;
    • Ogawa, Hiroomi;
    • Shirabe, Ken;
    • Saeki, Hiroshi
    Publication type:
    Article
    6
    7
    8

    ASO Visual Abstract: Conversion Surgery After Chemotherapy Plus Nivolumab as the First-Line Treatment for Unresectable Advanced or Recurrent Gastric Cancer and a Biomarker Study Using the Gustave Roussy Immune Score—A Multicenter Study.

    Published in:
    2024
    By:
    • Nakazawa, Nobuhiro;
    • Sohda, Makoto;
    • Hosoi, Nobuhiro;
    • Watanabe, Takayoshi;
    • Kumakura, Yuji;
    • Yamashita, Toshiki;
    • Tanaka, Naritaka;
    • Saito, Kana;
    • Kimura, Akiharu;
    • Kasuga, Kengo;
    • Nakazato, Kenji;
    • Yoshinari, Daisuke;
    • Shimizu, Hisashi;
    • Ubukata, Yasunari;
    • Hosaka, Hisashi;
    • Sano, Akihiko;
    • Sakai, Makoto;
    • Ogawa, Hiroomi;
    • Shirabe, Ken;
    • Saeki, Hiroshi
    Publication type:
    Abstract
    9

    Conversion Surgery After Chemotherapy Plus Nivolumab as the First-Line Treatment for Unresectable Advanced or Recurrent Gastric Cancer and a Biomarker Study Using the Gustave Roussy Immune Score: A Multicenter Study.

    Published in:
    Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2024, v. 31, n. 13, p. 9023, doi. 10.1245/s10434-024-16161-4
    By:
    • Nakazawa, Nobuhiro;
    • Sohda, Makoto;
    • Hosoi, Nobuhiro;
    • Watanabe, Takayoshi;
    • Kumakura, Yuji;
    • Yamashita, Toshiki;
    • Tanaka, Naritaka;
    • Saito, Kana;
    • Kimura, Akiharu;
    • Kasuga, Kengo;
    • Nakazato, Kenji;
    • Yoshinari, Daisuke;
    • Shimizu, Hisashi;
    • Ubukata, Yasunari;
    • Hosaka, Hisashi;
    • Sano, Akihiko;
    • Sakai, Makoto;
    • Ogawa, Hiroomi;
    • Shirabe, Ken;
    • Saeki, Hiroshi
    Publication type:
    Article
    10

    CD36 Expression Is Associated with Cancer Aggressiveness and Energy Source in Esophageal Squamous Cell Carcinoma.

    Published in:
    Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2021, v. 28, n. 2, p. 1217, doi. 10.1245/s10434-020-08711-3
    By:
    • Yoshida, Tomonori;
    • Yokobori, Takehiko;
    • Saito, Hideyuki;
    • Kuriyama, Kengo;
    • Kumakura, Yuji;
    • Honjo, Hiroaki;
    • Hara, Keigo;
    • Sakai, Makoto;
    • Miyazaki, Tatsuya;
    • Obinata, Hideru;
    • Erkhem-Ochir, Bilguun;
    • Gombodorj, Navchaa;
    • Sohda, Makoto;
    • Saeki, Hiroshi;
    • Kuwano, Hiroyuki;
    • Shirabe, Ken
    Publication type:
    Article
    11
    12
    13
    14
    15

    Correlation between high FBXW7 expression in pretreatment biopsy specimens and good response to chemoradiation therapy in patients with locally advanced esophageal cancer: A retrospective study.

    Published in:
    Journal of Surgical Oncology, 2018, v. 118, n. 1, p. 101, doi. 10.1002/jso.25127
    By:
    • Gombodorj, Navchaa;
    • Yokobori, Takehiko;
    • Tanaka, Naritaka;
    • Suzuki, Shigemasa;
    • Kuriyama, Kengo;
    • Kumakura, Yuji;
    • Yoshida, Tomonori;
    • Sakai, Makoto;
    • Sohda, Makoto;
    • Baatar, Seded;
    • Miyazaki, Tatsuya;
    • Nishiyama, Masahiko;
    • Shirabe, Ken;
    • Kuwano, Hiroyuki
    Publication type:
    Article
    16
    17

    Nuclear PROX1 is Associated with Hypoxia-Inducible Factor 1α Expression and Cancer Progression in Esophageal Squamous Cell Carcinoma.

    Published in:
    Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2015, v. 22, p. 1566, doi. 10.1245/s10434-015-4831-6
    By:
    • Yokobori, Takehiko;
    • Bao, Pinjie;
    • Fukuchi, Minoru;
    • Altan, Bolag;
    • Ozawa, Daigo;
    • Rokudai, Susumu;
    • Bai, Tuya;
    • Kumakura, Yuji;
    • Honjo, Hiroaki;
    • Hara, Keigo;
    • Sakai, Makoto;
    • Sohda, Makoto;
    • Miyazaki, Tatsuya;
    • Ide, Munenori;
    • Nishiyama, Masahiko;
    • Oyama, Tetsunari;
    • Kuwano, Hiroyuki
    Publication type:
    Article
    18
    19
    20